This article first appeared on GuruFocus .
Release Date: July 29, 2026
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
Positive Points
-
Anika Therapeutics Inc ( NASDAQ:ANIK ) reported a 17% increase in commercial channel revenue, marking a record level for the company.
-
The company achieved significant gross margin expansion to 65%, one of the highest levels in recent years.
-
International revenue reached a record $12.6 million, increasing 22% year-over-year, driven by broad-based growth across markets and product categories.
-
Adjusted EBITDA for the quarter was $7.1 million, representing an adjusted EBITDA margin of 22%, the strongest quarterly profitability performance since 2020.
-
Anika Therapeutics Inc ( NASDAQ:ANIK ) raised its full-year 2026 guidance, expecting total company revenue growth of 5% to 10% and adjusted EBITDA margin guidance to 13% to 17%.
Negative Points
-
The company noted potential revenue variability due to customer ordering patterns, which could impact future quarters.
-
There is ongoing pricing pressure in the OEM channel, which could affect future profitability despite volume growth.
-
The timing of regulatory approval for Hyalafast in the U.S. remains uncertain, potentially impacting future revenue projections.
-
Cash generation has lagged behind other metrics, with expectations for stronger free cash flow pushed to the second half of the year.
-
The company faces challenges in maintaining the favorable product mix that contributed to the current gross margin levels.
Q & A Highlights
Q: The guidance implies a significant sequential step down in OEM revenue for the second half. Is this due to order timing or visibility into second-half pricing or volume? A: Steve Griffin, CEO: The sequential step down is partly due to favorable order timing in the second quarter, which contributed between $1 million and $2 million. Additionally, the fourth quarter of last year was particularly strong, which affects the comparison. Despite this, we are pleased with the overall performance and have raised our guidance to reflect year-over-year growth in the OEM channel.
Q: Gross margin has been above 60% for three consecutive quarters. What are the main drivers, and are these levels sustainable? A: Steve Griffin, CEO: Yes, we expect to operate in the mid-60s range. The main drivers include our lean transformation efforts, which focus on eliminating waste and improving productivity. We've increased output without raising operating expenses and improved yields. We are still in the early stages of these improvements and see further opportunities to create value.
Q: Can you provide an update on the bioequivalence study enrollment for Singal? Does the current pace support completion within 2026? A: Steve Griffin, CEO: Yes, the bioequivalence study is progressing as expected, and enrollment remains on track to be completed around year-end 2026. There have been no changes to our expectations.
Q: Regarding the sustainability of gross margin in the mid-60s, will productivity improvements in manufacturing fill the gap if favorable order timing doesn't continue? A: Steve Griffin, CEO: We started the year with gross margins at 64% and 65%. While there is always some volatility, we expect to maintain around 64% in the second half. The gains from improved yields and throughput will continue to flow through, supporting this level.
Q: What are your expectations for pricing over the next 6 to 12 months for Montevis Ortho? A: Steve Griffin, CEO: We maintain close communication with J&J and DePuy Synthes. We expect some price erosion offset by volume increases. Pricing will continue to be a headwind, but volume should more than offset it, leading to overall revenue growth for Monobisk.
For the complete transcript of the earnings call, please refer to the full earnings call transcript .
